Ocugen Inc Share Price Today: Live Updates & Key Insights

Ocugen Inc share price today is $2.02, up -8.93%. The stock opened at $2.24 against the previous close of $2.24, with an intraday high of $2.28 and low of $2.01.

Ocugen Inc Share Price Chart

Ocugen Inc

us-stock
To Invest in {{usstockname}}
us-stock

Ocugen Inc Share Price Performance

$2.02 -0.0893(-8.93%) OCGN at 23 Mar 2026 02:34 PM Biotechnology
Lowest Today 2.01
Highest Today 2.28
Today’s Open 2.24
Prev. Close 2.24
52 Week High 2.73
52 Week Low 0.57
Day’s Range: Low 2.01 High 2.28
52-Week Range: Low 0.57 High 2.73
1 day return -
1 Week return -13.06
1 month return +24.15
3 month return +36.24
6 month return +45.0
1 year return +216.19
3 year return +120.65
5 year return -76.14
10 year return -

Ocugen Inc Institutional Holdings

Vanguard Group Inc 5.02

Vanguard Total Stock Mkt Idx Inv 2.99

Millennium Management LLC 1.65

GMT Capital Corp 1.27

BlackRock Inc 1.24

Geode Capital Management, LLC 1.16

Vanguard Institutional Extnd Mkt Idx Tr 1.05

Stt Strt®SPDR®S&PKenshoNwEcosComposETF 0.79

Marshall Wace Asset Management Ltd 0.77

Renaissance Technologies Corp 0.52

Jane Street Group LLC 0.52

Fidelity Extended Market Index 0.50

Citadel Advisors Llc 0.42

State Street Corp 0.41

Susquehanna International Group, LLP 0.35

iShares Core S&P Total US Stock Mkt ETF 0.34

UBS Group AG 0.31

Hennion & Walsh Asset Management Inc 0.31

Rinkey Investments 0.30

Vanguard Health Care ETF 0.29

CI Private Wealth LLC 0.27

GSA Capital Partners LLP 0.27

Blackrock Extended Mkt Fund CF 0.23

Two Sigma Investments LLC 0.21

Extended Equity Market Fund K 0.20

Northern Trust Corp 0.18

Fidelity Total Market Index 0.18

iShares Genomics Immnlgy & Hlthcr ETF 0.15

XTX Topco Ltd 0.14

Fidelity Series Total Market Index 0.13

Spartan Extended Market Index Pool F 0.13

NT Ext Equity Mkt Idx Fd - L 0.11

Royal Bank of Canada 0.10

Galileo - Biotech Innovation Fund S USD 0.10

Northern Trust Extended Eq Market Idx 0.09

BlackRock Global Equity Mkt Netrl Instl 0.09

NT Ext Equity Mkt Idx Fd - NL 0.09

Vanguard Instl Ttl Stck Mkt Idx Tr 0.08

Spartan Total Market Index Pool G 0.08

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.07

Ocugen Inc Market Status

Strong Buy: 2

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

Ocugen Inc Fundamentals

Market Cap 668.91 M

PB Ratio 149.1609

PE Ratio 0.0

Enterprise Value 681.84 M

Total Assets 43.52 M

Volume 25070003

Ocugen Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:22920 0.0M, FY20:42620 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:42620 0.0M, FY19:null 0.0M

Annual Net worth FY23:-75524000 -75.5M, FY22:-77834000 -77.8M, FY21:-58365000 -58.4M, FY20:-22623468 -22.6M, FY19:-21225593 -21.2M

Quarterly Revenue Q3/2025:1752000 1.8M, Q2/2025:1373000 1.4M, Q1/2025:1481000 1.5M, Q3/2024:1136000 1.1M, Q2/2024:1141000 1.1M

Quarterly Profit Q3/2025:1752000 1.8M, Q2/2025:1373000 1.4M, Q1/2025:1481000 1.5M, Q3/2024:1136000 1.1M, Q2/2024:-7761000 -7.8M

Quarterly Net worth Q3/2025:-20051000 -20.1M, Q2/2025:-14739000 -14.7M, Q1/2025:-15350000 -15.4M, Q3/2024:-12970000 -13.0M, Q2/2024:-15280000 -15.3M

About Ocugen Inc & investment objective

Company Information Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Organisation Biotechnology

Employees 116

Industry Biotechnology

CEO Dr. Shankar Musunuri M.B.A., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Ocugen Inc FAQs

What is the share price of Ocugen Inc today?

The current share price of Ocugen Inc is $2.02.

Can I buy Ocugen Inc shares in India?

Yes, Indian investors can buy Ocugen Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Ocugen Inc shares in India?

You can easily invest in Ocugen Inc shares from India by:

Can I buy fractional shares of Ocugen Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Ocugen Inc?

Ocugen Inc has a market cap of $668.91 M.

In which sector does Ocugen Inc belong?

Ocugen Inc operates in the Biotechnology sector.

What documents are required to invest in Ocugen Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Ocugen Inc?

The PE ratio of Ocugen Inc is N/A and the PB ratio is 149.16.